Ociperlimab/Tislelizumab Plus cCRT Bolsters PFS/Responses in LS-SCLC

Treatment with tislelizumab (Tevimbra) in combination with concurrent chemoradiotherapy (cCRT) with or without ociperlimab, may improve progression-free survival (PFS) and response rates among patients with first-line limited-stage small cell…